<code id='93099C9F95'></code><style id='93099C9F95'></style>
    • <acronym id='93099C9F95'></acronym>
      <center id='93099C9F95'><center id='93099C9F95'><tfoot id='93099C9F95'></tfoot></center><abbr id='93099C9F95'><dir id='93099C9F95'><tfoot id='93099C9F95'></tfoot><noframes id='93099C9F95'>

    • <optgroup id='93099C9F95'><strike id='93099C9F95'><sup id='93099C9F95'></sup></strike><code id='93099C9F95'></code></optgroup>
        1. <b id='93099C9F95'><label id='93099C9F95'><select id='93099C9F95'><dt id='93099C9F95'><span id='93099C9F95'></span></dt></select></label></b><u id='93099C9F95'></u>
          <i id='93099C9F95'><strike id='93099C9F95'><tt id='93099C9F95'><pre id='93099C9F95'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:324

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Drug for rare kidney disease narrowly misses mark in clinical trial
          Drug for rare kidney disease narrowly misses mark in clinical trial

          AdobeTravereTherapeuticssaidThursdaythatastudymeanttoconfirmthebenefitofitsnewlyapproveddrugforarare

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          FDA panel to weigh approval of NurOwn, controversial ALS drug

          AdobeYearsofpolarizingscientificdiscourseandbruisingonlinedebatewillcometoaheadnextweekwhenadviserst